

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 – 3 (cancelled)

Claim 4 (currently amended): A glycoprotein extracted from blood serum, intercellular space of tissues of liver, thymus or eye of human beings and animals by using isoelectric focusing, the glycoprotein being soluble in saturated (100%) solution of ammonium sulphate, having apparent molecular weight of 10-45 kDa and having specific biological activity to influence viscoelastic properties of hepatocyte membranes in ultra low doses from 10^{-12} to 10^{-29} mol/liter, said specific biological activity to influence viscoelastic properties of hepatocyte membranes is determined by the amount of cellular nuclei released during dispersing according to the formula: $E_a = 200\% - (N_{on}/N_k) \times 100\%$, where E_a is biological effect caused by the glycoprotein, N_{on} and N_k are the amount of cell nuclei released from 1 mg of tissue culture with the glycoprotein and tissue culture without the glycoprotein, respectively and lower.

Claim 5 (previously presented): A pharmaceutical composition comprising the glycoprotein of claim 4 in an effective amount and a pharmaceutically acceptable carrier.

Claim 6 (previously presented): A method of using the glycoprotein of claim 4 comprising the step of administering the glycoprotein to a subject as a medicinal agent.

Claims 7 – 9 (cancelled)